Pfizer (NYSE: PFE) and Merck (NYSE: MRK) have underperformed compared to broader equities in 2023, with both companies reporting lackluster financial results and facing uncertainty due to impending patent expirations. They may achieve significant advancements by 2026, but investors must evaluate which company presents a better opportunity as the new year approaches. The outlook for both firms remains a critical consideration for investment decisions. Further analysis is needed to determine the more favorable option for investors.
Loading PerspectiveSplit analysis...
